Steroids are the mainstay therapy in chronic graft-versus-host disease, but there remains a need for more targeted treatments, of which there have been recent advances made with the availability of therapies that may translate into improved patient outcomes. What are these newer immunomodulatory agents and what is the clinical evidence behind their use? Our host, Dr. Dennis Kim, takes a deep look into this topic with Dr. Gizelle Popradi, Director of the McGill University Health Centre Stem Cell Transplant Program and Clinical Teaching Unit Director of the Hematology-Transplant Unit, in the Department of Internal Medicine and Division of Hematology, as well as an Assistant Professor at McGill University.

This episode discusses the unmet treatment needs  ...